Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 1

Status

Completed 15Active not recruiting 11Recruiting 9Terminated 7Not yet recruiting 6Withdrawn 3Unknown 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 1Infiltrating Bladder Urothelial Carcinoma 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Cystectomy × Clear all
NCT02845050 2018-02-13

JaNEO

Ligartis GmbH

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT03238664 2018-01-02

Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors

University of Southern California

Phase NA Withdrawn
Genitourinary

Carcinoma, Transitional Cell

NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡